Table 4

 Core American College of Rheumatology component responses at 1 and 2 years

ACR componentAbatacept 2 mg/kg switched to 10 mg/kg+etanercept*Placebo switched to abatacept 10 mg/kg+etanercept†
1 year2 yearsChange1 year2 yearsChange
ACR, American College of Rheumatology; CRP, C reactive protein; mHAQ, modified Health Assessment Questionnaire.
All patients received etanercept 25 mg twice weekly; values for year 3 were recorded but excluded owing to the small sample number.
All values are shown as mean (SD).
*n = 46–51; †n = 19–20; ‡68 joints were assessed for tenderness; §p = 0.002; ¶66 joints were assessed for swelling; **p<0.001; ††p = 0.018; ‡‡p = 0.0135; §§reference range, 0–0.4 mg/dl.
Tender joints‡10.6 (12.9)6.4 (8.8)−4.2 (9.4)§14.1 (10.7)11.1 (13.4)−3.0 (8.2)
Swollen joints¶10.4 (9.5)6.0 (5.7)−4.4 (8.3)**12.9 (9.4)8.7 (9.3)−4.2 (7.3)††
Patient assessment of pain34.5 (23.5)29.2 (19.8)−5.3 (26.3)30.3 (22.6)33.1 (19.8)2.8 (15.7)
Patient assessment of function (mHAQ)0.5 (0.4)0.4 (0.4)−0.1 (0.3)0.5 (0.4)0.5 (0.4)0 (0.2)
Patient assessment of disease activity32.1 (22.3)28.0 (19.4)−4.1 (23.1)29.4 (17.7)31.0 (19.8)1.6 (19.4)
Physician assessment of disease activity27.4 (19.0)19.8 (17.0)−7.6 (20.6)‡‡25.4 (17.0)24.8 (19.2)−0.6 (23.1)
CRP level§§1.0 (1.1)0.8 (0.7)−0.2 (0.9)1.0 (0.8)0.6 (0.5)−0.4 (0.8)